Page 13 - Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma

CUAJ – Consensus Statement Warren et al
Unresectable locally advanced and metastatic urothelial carcinoma

14. Hussain M, Vaishampayan U, Du W. Combination paclitaxel, carboplatin and
gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol
2001;19:2527-33.
15. Galsky MD, Iasonos A, Mironov S. Phase II trial of dose-dense doxorubicin plus
gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial
carcinoma and impaired renal function. Cancer 2007;109:549-55.
16. Meluch AA, Greco FA, Burris HA, et al. Paclitaxel and gemcitabine chemotherapy for
advanced transitional-cell carcinoma of the urothelial tract: A phase II trial of the Minnie
Pearl Cancer Research Network. J Clin Oncol 2001;19:3018-24.
17. Calabrò F, Lorusso V, Rosati G, et al. Gemcitabine and paclitaxel every 2 weeks in
patients with previously untreated urothelial carcinoma. Cancer 2009;115:2652-59.
18. Kaufman DS, Carducci MA, Kuzel TM, et al. A multi-institutional phase II trial of
gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial
cancer. Urol Oncol 2004;22:393-97.
19. Li J, Juliar B, Yiannoutsos C, et al. Weekly paclitaxel and gemcitabine in advanced
transitional-cell carcinoma of the urothelium: A phase II Hoosier Oncology Group study.
J Clin Oncol 2005;23:1185-91.
20. Ardavanis A, Tryfonopoulos D, Alexopoulos A, et al. Gemcitabine and docetaxel as first-
line treatment for advanced urothelial carcinoma: A phase II study. Br J Cancer
2005;92:645-50.
21. Gitlitz BJ, Baker C, Chapman Y, et al. A phase II study of gemcitabine and docetaxel
therapy in patients with advanced urothelial carcinoma. Cancer 2003;98:1863-69.
22. de Wit R, Kruit WHJ, Stoter G, et al. Docetaxel (Taxotere): An active agent in metastatic
urothelial cancer; Results of a phase II study in non-chemotherapy-pretreated patients. Br
J Cancer 1998;78:1342-45.
23. Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced
transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative
Oncology Group. J Clin Oncol 1994;12:2264-70.
24. Moore MJ, Tannock IF, Ernst DS, et al. Gemcitabine: A promising new agent in the
treatment of advanced urothelial cancer. J Clin Oncol 1997;15:3441-45.
25. Stadler WM, Kuzel T, Roth B, et al. Phase II study of single-agent gemcitabine in
previously untreated patients with metastatic urothelial cancer. J Clin Oncol.
1997;15:3394-98.
26. Balar AV, Castellano D, O’Donnell PH, et al. First-line pembrolizumab in cisplatin-
ineligible patients with locally advanced and unresectable or metastatic urothelial cancer
(KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18:1483-
92.
27. Vuky J, Balar A V, Castellano DE. et al. Updated efficacy and safety of KEYNOTE-052:
A single arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-
ineligible advanced urothelial cancer (UC). J Clin Oncol. 2018;36;15S:4524.
28. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in
cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a
single-arm, multicentre, phase 2 trial. Lancet 2017;389:67-76.
29. Oing C, Rink M, Oechsle K, Seidel C, et al. Second line chemotherapy for advanced and